Skip to main content
Explore URMC

Andrew D. Goodman, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-7854

Administrative: (585) 275-7854

Office: (585) 275-7854

Fax: (585) 275-9953

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentNot Accepting New Patients

Faculty Appointments

Patient Care Setting



Professional Background

Andrew D. Goodman, MD is Professor of Neurology, Chief of the Neuroimmunology Unit, and Director of the Multiple Sclerosis Center at the University of Rochester.

Dr. Goodman is a graduate of Rutgers College and the University of Medicine and Dentistry of New Jersey; he did residency training in internal medicine and neurology at Mt. Sinai Medical Center in New York City. He completed a research fellowship in the Neuroimmunology Branch at the National Institutes of Health, Bethesda, Maryland.

Numerous publications reflect his interests in clinical and experimental therapeutics research as well as the immunology and virology of multiple sclerosis. Dr. Goodman has been principal investigator and a member of national and international steering committees for numerous clinical trials of new therapies for multiple sclerosis.

Dr. Goodman is a past Chair of the Multiple Sclerosis Section of the American Academy of Neurology. He has served the National Multiple Sclerosis Society as Deputy Medical Officer, Co-Chair of the Long-term Care Committee, member of the Client Education Committee, and member of the Executive Committee of the National Clinical Advisory Board.



MD | Rutgers New Jersey Medical School

Post-doctoral Training & Residency

07/01/1983 - 06/30/1988
Fellowship in Neurology at National Institutes of Health, NIH

07/01/1979 - 06/30/1980
Residency in Internal Medicine at Mount Sinai Hospital

07/01/1979 - 06/30/1983
Residency in Neurology at Mount Sinai Hospital

VIEW ALL expand_more


Fellow, American Academy of Neurology

Impact Presentation Award, Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Location: Vienna

Senior Faculty Award
Sponsor: University of Rochester Department of Neurology
Location: Rochester, NY

Inductee, Volunteer Hall of Fame
Sponsor: US National Multiple Sclerosis Society
Location: New Orleans, LA

1999 - 2000
Chair, Multiple Sclerosis Section
Sponsor: American Academy of Neurology

1998 - Present
Named in Best Doctors in America

1998 - 1999
Chair-elect, Multiple Sclerosis Section
Sponsor: American Academy of Neurology

University of Rochester Neurology Resident Faculty Teaching Award
Location: Rochester, NY

1996 - Present
Named in Best Doctors in America: Northeast.

1982 - 1983
Chief Neurology Resident
Location: Mount Sinai Medical Center

Alpha Omega Alpha

A.B. with Distinction in Biochemistry

1973 - 1974
Henry Rutgers Scholar

VIEW ALL expand_more

Clinical Trials

A Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Lead Researcher: Andrew D Goodman

The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability, as assessed by sustained Expanded Disability Status Scale (EDSS) improvement at 12 months in Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary progressive multiple sclerosis [PPMS] and secondary progressive multiple sclerosis [SPMS]).

View Study Details

A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease,A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease

Lead Researcher: Andrew D Goodman

Determine the difference in disability at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo. Inclusion Criteria 1. Diagnosis of NMDAR encephalitis 2. Age ≥ 18 years 3. Change in mental status

View Study Details


Journal Articles

Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L, . "Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial." Lancet.. 2016 Mar 12; 387(10023):1075-1084. Epub 2016 Jan 28.

Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ. "Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial." Clinical therapeutics.. 2015 Dec 1; 37(12):2780-7. Epub 2015 Nov 10.

Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR, Blight AR, . "Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials." Multiple sclerosis : clinical and laboratory research.. 2015 Sep; 21(10):1322-31. Epub 2015 Jan 12.




Andrew Goodman, M.D., Discusses New Drug for Multiple Sclerosis


SECOND OPINION | Multiple Sclerosis | APT | Full Episode


SECOND OPINION | Multiple Sclerosis | APT | Webisode